Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX) Sees Large Drop in Short Interest

Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX - Get Free Report) was the target of a large decrease in short interest in April. As of April 15th, there was short interest totalling 141,400 shares, a decrease of 37.4% from the March 31st total of 226,000 shares. Approximately 1.8% of the shares of the stock are sold short. Based on an average daily volume of 1,400,000 shares, the days-to-cover ratio is presently 0.1 days.

Cumberland Pharmaceuticals Trading Down 6.4 %

Cumberland Pharmaceuticals stock traded down $0.31 during trading hours on Friday, hitting $4.50. The stock had a trading volume of 21,042 shares, compared to its average volume of 866,644. The business's 50 day simple moving average is $4.79 and its 200-day simple moving average is $3.21. Cumberland Pharmaceuticals has a one year low of $1.04 and a one year high of $7.25. The stock has a market cap of $62.86 million, a price-to-earnings ratio of -5.84 and a beta of -0.24. The company has a quick ratio of 0.99, a current ratio of 1.13 and a debt-to-equity ratio of 0.41.

Cumberland Pharmaceuticals (NASDAQ:CPIX - Get Free Report) last issued its quarterly earnings data on Tuesday, March 4th. The specialty pharmaceutical company reported ($0.03) earnings per share (EPS) for the quarter. Cumberland Pharmaceuticals had a negative net margin of 29.54% and a negative return on equity of 9.50%. The business had revenue of $10.44 million during the quarter.

Institutional Trading of Cumberland Pharmaceuticals

An institutional investor recently raised its position in Cumberland Pharmaceuticals stock. Two Sigma Investments LP lifted its stake in shares of Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX - Free Report) by 94.3% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 37,649 shares of the specialty pharmaceutical company's stock after acquiring an additional 18,271 shares during the quarter. Two Sigma Investments LP owned approximately 0.27% of Cumberland Pharmaceuticals worth $89,000 as of its most recent filing with the Securities and Exchange Commission (SEC). Institutional investors own 15.51% of the company's stock.

Wall Street Analyst Weigh In

Separately, StockNews.com upgraded shares of Cumberland Pharmaceuticals from a "hold" rating to a "buy" rating in a research report on Thursday, March 6th.

Cumberland Pharmaceuticals Company Profile

Cumberland Pharmaceuticals Inc, a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products for hospital acute care, gastroenterology, and oncology in the United States and internationally. The company offers Acetadote, an injection for the treatment of acetaminophen poisoning; Caldolor, an injection for the treatment of pain and fever; Kristalose, a prescription laxative oral solution for the treatment of constipation; Omeclamox-Pak for the treatment of Helicobacter pylori infection and duodenal ulcer disease; Vaprisol, an injection for treating euvolemic and hypervolemic hyponatremia; Sancuso, an injection for the treatment of chemotherapy treatment; and Vibativ, an injection for the treatment of certain serious bacterial infections, including hospital-acquired and ventilator-associated bacterial pneumonia, as well as complicated skin and skin structure infections.